Premaitha Health Share Forecast, Price & News

GBX 9.10
+0.20 (+2.25 %)
(As of 11/6/2018)
Today's Range
50-Day Range
52-Week Range
Volume1.57 million shs
Average Volume1.35 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive NIPT News and Ratings via Email

Sign-up to receive the latest news and ratings for Premaitha Health and its competitors with MarketBeat's FREE daily newsletter.

Premaitha Health logo

About Premaitha Health

Premaitha Health PLC, a molecular diagnostic company, develops tests for non-invasive prenatal screening and other applications in the United Kingdom and internationally. The company develops the IONA Test, an in vitro diagnostic non-invasive pre-natal screening test for pregnant women to estimate Down's syndrome, Edward's syndrome, and Patau's syndrome. The IONA test is a diagnostic system that enables clinical laboratory customers to perform the test in their own facilities. The company is headquartered in Manchester, the United Kingdom.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

0.64 out of 5 stars

Analyst Opinion: 0.0Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Premaitha Health (LON:NIPT) Frequently Asked Questions

What stocks does MarketBeat like better than Premaitha Health?

Wall Street analysts have given Premaitha Health a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Premaitha Health wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Premaitha Health's earnings last quarter?

Premaitha Health PLC (LON:NIPT) released its quarterly earnings results on Friday, December, 29th. The company reported ($2.00) earnings per share (EPS) for the quarter. The company had revenue of $2.71 million for the quarter.
View Premaitha Health's earnings history

Who are Premaitha Health's key executives?

Premaitha Health's management team includes the following people:
  • Dr. Stephen Little, Exec. Vice Chairman (Age 61)
  • Mr. Barry Hextall, CFO, Sec. & Exec. Director
  • Mr. Peter Collins, Chief Bus. Officer & Exec. Director (Age 59)
  • Mr. Lyn Fafydd Rees, CEO & Director (Age 45)
  • Dr. Chia-Han Chan, Chief Scientific Officer & Director (Age 42)

Who are some of Premaitha Health's key competitors?

What other stocks do shareholders of Premaitha Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Premaitha Health investors own include IQE (IQE), Avanti Communications Group (AVN), Chesapeake Utilities (CPK), (PLE.L) (PLE), Vedanta Resources (VED), Mitie Group (MTO), Scancell (SCLP), Sirius Minerals (SXX), Advanced Micro Devices (AMD) and Aviva (AV).

What is Premaitha Health's stock symbol?

Premaitha Health trades on the London Stock Exchange (LON) under the ticker symbol "NIPT."

How do I buy shares of Premaitha Health?

Shares of NIPT and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Premaitha Health's stock price today?

One share of NIPT stock can currently be purchased for approximately GBX 9.10.

What is Premaitha Health's official website?

The official website for Premaitha Health is www.premaitha.com.

Where are Premaitha Health's headquarters?

Premaitha Health is headquartered at Rutherford House, 40 Pencroft Way, MANCHESTER, M15 6SZ, United Kingdom.

How can I contact Premaitha Health?

Premaitha Health's mailing address is Rutherford House, 40 Pencroft Way, MANCHESTER, M15 6SZ, United Kingdom. The company can be reached via phone at +44-161-6676865.

This page was last updated on 7/29/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.